Stereotactic Body Radiotherapy in lung cancer and lung metastases patient at Siriraj hospital

Authors

  • Utumporn Puangragsa Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Siwadol Pleanarom Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Wisawa Phongprapun Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Udomsak Thananphuwasit Division of radiation oncology, Department of radiology, Faculty of medicine, Siriraj hospital, Mahidol University, Bangkok
  • Chatchawan Yaemchaisarn Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Favalai Pongpaiboon Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Janjira Petsuksiri Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Jiraporn Setakornnukul Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University

Keywords:

stereotactic body radiotherapy, treatment guideline, lung cancer

Abstract

Stereotactic body radiation therapy (SBRT) or stereotactic ablative radiation therapy (SABR) is a modern advanced radiotherapy technique. Due to its high dosage per fraction, this technique requires more accuracy and precision than the conventional technique. In the thoracic region, there are many indications for SBRT such as early-stage non-small cell lung cancer and oligo-lung metastases. This treatment usually involves and may affect normal tissue of complex organs such as bronchus, heart, lung, vessel, esophagus, spinal cord, chest wall, and brachial plexus. Breathing motion is also considered an essential factor affecting the movement of the tumor and nearby normal organs during treatment which leads to not only underdosage for target tissue, but also causes unnecessary normal tissue damage. To alleviate this, respiratory motion management is necessary for SBRT in lung tumors. There are five respiratory motion management techniques, i.e., envelope technique, breath hold technique, force shallow breathing with abdominal compression technique, gating and tracking motion technique. The application of these techniques depends on the radiotherapy machine between a general linear accelerator with an image-guided radiotherapy system and a dedicated radiotherapy machine for stereotactic radiotherapy. Besides motion management, treatment planning and plan evaluation are also delicate and meticulous processes when treating a patient with the SBRT technique. This article will review the current clinical practice guideline of SBRT in lung tumors with the machines at the division of Radiation Oncology, department of Radiology, Faculty of Medicine, Siriraj hospital.

References

Guckenberger M, Andratschke N, Alheit H, Holy R, Moustakis C, Nestle U, et al. Definition of stereotactic body radiotherapy. Strahlenther Onkol. 2014;190:26-33.

Videtic GMM, Donington J, Giuliani M, Heinzerling J, Karas TZ, Kelsey CR, et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol. 2017;7:295-301.

Schneider BJ, Daly ME, Kennedy EB, Antonoff MB, Broderick S, Feldman J, et al. Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. J Clin Oncol. 2018 Mar 1;36:710-719.

Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17:1672-82.

Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019;37:1558-65.

Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer. JAMA Oncol. 2018;4:e173501.

Keall PJ, Mageras GS, Balter JM, Emery RS, Forster KM, Jiang SB, et al. The management of respiratory motion in radiation oncology report of AAPM Task Group 76a). Med Phys. 2006;33:3874-900.

Seppenwoolde Y, Shirato H, Kitamura K, Shimizu S, Van Herk M, Lebesque JV, et al. Precise and real-time measurement of 3D tumor motion in lung due to breathing and heartbeat, measured during radiotherapy. Int J Radiat Oncol Biol Phys. 2002;53:822-34.

Rietzel E, Liu AK, Doppke KP, Wolfgang JA, Chen AB, Chen GTY, et al. Design of 4D treatment planning target volumes. Int J Radiat Oncol Biol Phys. 2006;66:287-95.

Xi M, Liu M-Z, Zhang L, Li Q-Q, Huang X-Y, Liu H, et al. How many sets of 4DCT images are sufficient to determine internal target volume for liver radiotherapy? Radiother Oncol. 2009;92:255-9.

Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, Deluca J, et al. Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer. J Clin Oncol. 2006;24:4833-9.

oncology N. Lung Cancer Atlases, Templates, & Tools: RTOG group; [cited 2022]. Available from: https://www.nrgoncology.org/ciro-lung.

Chang JY, Bezjak A, Mornex F. Stereotactic Ablative Radiotherapy for Centrally Located Early Stage Non–Small-Cell Lung Cancer: What We Have Learned. J Thorac Oncol. 2015;10:577-85.

Consortrium SU. Stereotactic Ablative Body Radiation Therapy (SABR). 2019.

Guckenberger M, Andratschke N, Dieckmann K, Hoogeman MS, Hoyer M, Hurkmans C, et al. ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiother Oncol. 2017;124:11-7.

Incorporated A. CyberKnife System V11.1 Traetment Planning Course Workbook2019.

Videtic GMM, Hu C, Singh AK, Chang JY, Parker W, Olivier KR, et al. A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys. 2015;93:757-64.

Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: The report of AAPM Task Group 101. Med Phys. 2010;37:4078-101.

Fernando HC, Timmerman R. American College of Surgeons Oncology Group Z4099/Radiation Therapy Oncology Group 1021: A randomized study of sublobar resection compared with stereotactic body radiotherapy for high-risk stage I non–small cell lung cancer. J Thorac Cardiovasc Surg. 2012;144:S35-S8.

Gerhard SG, Palma DA, Arifin AJ, Louie AV, Li GJ, Al-Shafa F, et al. Organ at Risk Dose Constraints in SABR: A Systematic Review of Active Clinical Trials. Pract Radiat Oncol. 2021;11:e355-e365.

Chang JY, Li QQ, Xu QY, Allen PK, Rebueno N, Gomez DR, et al. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone". Int J Radiat Oncol Biol Phys. 2014;88:1120-8.

Bezjak A, Paulus R, Gaspar LE, Timmerman RD, Straube WL, Ryan WF, et al. Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial. J Clin Oncol. 2019;37:1316-25.

Timmerman R. A Story of Hypofractionation and the Table on the Wall. Int J Radiat Oncol Biol Phys. 2022;112:4-21.

Li Q, Swanick CW, Allen PK, Gomez DR, Welsh JW, Liao Z, et al. Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications. Radiother Oncol. 2014;112:256-61.

Linda A, Trovo M, Bradley JD. Radiation injury of the lung after stereotactic body radiation therapy (SBRT) for lung cancer: a timeline and pattern of CT changes. Eur J Radiol. 2011;79:147-54.

Dahele M, Palma D, Lagerwaard F, Slotman B, Senan S. Radiological changes after stereotactic radiotherapy for stage I lung cancer. J Thorac Oncol. 2011;6:1221-8.

Downloads

Published

2022-06-29

How to Cite

1.
Puangragsa U, Pleanarom S, Phongprapun W, Thananphuwasit U, Yaemchaisarn C, Pongpaiboon F, Petsuksiri J, Setakornnukul J. Stereotactic Body Radiotherapy in lung cancer and lung metastases patient at Siriraj hospital. J Thai Assn of Radiat Oncol [Internet]. 2022 Jun. 29 [cited 2024 Nov. 15];28(1):O49-O71. Available from: https://he01.tci-thaijo.org/index.php/jtaro/article/view/254419

Issue

Section

Review articles